CSS
CMPX icon

Cubist Systematic Strategies’s Compass Therapeutics CMPX Stock Holding History

Cubist Systematic Strategies’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,701
Closed -$40.7K – 3041
2024
Q2 		$40.7K Buy
+40,701
New +$59.4K ﹤0.01% 2725
2023
Q2 		– Sell
-51,576
Closed -$169K – 3610
2023
Q1 		$169K Buy
51,576
+41,276
+401% +$162K ﹤0.01% 3293
2022
Q4 		$51.8K Buy
+10,300
New +$41.1K ﹤0.01% 3900

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Cubist Systematic Strategies's CMPX Position: Q3 2024 in Review

Cubist Systematic Strategies sold out of Compass Therapeutics (CMPX) in Q3 2024, closing a stake of 40,701 shares — an estimated $40.7K sold.

Cubist Systematic Strategies first reported a position in CMPX in Q4 2022 and held it in 3 quarters. The position peaked at $169K in Q1 2023. 79 funds tracked by Wall St. Rank hold CMPX as of Q3 2024.

  • Cubist Systematic Strategies reported no remaining Compass Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 40,701 Compass Therapeutics shares in Q3 2024, an estimated $40.7K.
  • Cubist Systematic Strategies first reported a position in Compass Therapeutics in Q4 2022 and held it in 3 quarters.
  • Cubist Systematic Strategies's Compass Therapeutics position peaked at $169K in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2024.

Based on Cubist Systematic Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.